PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.68%
EBIT growth below 50% of AGEN's 63.13%. Michael Burry would suspect deeper competitive or cost structure issues.
22.68%
Operating income growth under 50% of AGEN's 60.31%. Michael Burry would be concerned about deeper cost or sales issues.
22.99%
Net income growth under 50% of AGEN's 54.43%. Michael Burry would suspect the firm is falling well behind a key competitor.
38.32%
EPS growth at 50-75% of AGEN's 55.71%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
38.32%
Diluted EPS growth at 50-75% of AGEN's 55.59%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
24.80%
Share count expansion well above AGEN's 2.80%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.80%
Diluted share count expanding well above AGEN's 2.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.87%
Similar OCF growth to AGEN's 24.15%. Walter Schloss would assume comparable operations or industry factors.
22.60%
FCF growth 75-90% of AGEN's 25.23%. Bill Ackman might push for improved capital allocation or operational changes to match the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13974.70%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
19.53%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
73.45%
Positive 3Y OCF/share CAGR while AGEN is negative. John Neff might see a big short-term edge in operational efficiency.
-5088.50%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
66.11%
5Y net income/share CAGR above 1.5x AGEN's 41.34%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
78.36%
3Y net income/share CAGR 1.25-1.5x AGEN's 55.64%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
2877.65%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
75.50%
Positive 5Y equity/share CAGR while AGEN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-75.29%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Negative asset growth while AGEN invests at 0.86%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-36.19%
We have a declining book value while AGEN shows 2.85%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-16.18%
We cut SG&A while AGEN invests at 6.25%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.